Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial.
Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, Mureddu G, Pede S, Maggioni AP, Lucci D, Reboldi G, Cardio-Sis investigators. Lancet. 2009 Aug 15;374(9689):525-33
It has long been recognized from epidemiologic studies that cardiovascular risk increases at blood pressures far below the current hypertension treatment target of 140/90. This open-label, blinded endpoint study randomized patients with uncontrolled hypertension to a systolic BP target of <130 mm Hg or <140 mm Hg. They showed a reduction in both the primary endpoint of electrocardiographic LVH and the secondary pre-specificed endpoint, a composite of clinical cardiovascular endpoints. Nephrology Now readers will likely be interested in reviewing the recent Cochrane Review entitled Treatment blood pressure targets for hypertension. which suggested no benefit to lower BP targets based on existing data.
Related Articles:
- Treatment blood pressure targets for hypertension.
- Secondary analysis of the CHOIR trial epoetin-|[alpha]| dose and achieved hemoglobin outcomes
- Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus
October 18th, 2009 at 10:28 pm
Commentary from the American College of Cardiology
http://cs.acc.org/cjrpicks/CJRPick.asp?cjrID=5403